CEOi - Global CEO Initiative on Alzheimer's Disease

The future of an Alzheimer’s diagnosis starts with an Alzheimer's blood test. Here’s how individuals like Suzanne Schindler, a Neurologist at Washington University School of Medicine and Blood-Based Biomarker (BBM) Workgroup Co-Lead, are making them a reality.    Our Blood-based Biomarker Workgroup, led by Suzanne Schindler and Oskar Hansson, united over 90 experts to develop performance standards for clinicians and health systems, facilitating the widespread adoption of Alzheimer's blood tests.    Discover the full impact of Alzheimer’s blood tests in our latest video below, featuring Suzanne and check out the full recommendations in our recent publication in @ Nature Reviews Neurology here: https://lnkd.in/eaReXM3Q   There’s still time to register for our lunch and panel discussion with leading Alzheimer’s experts on the sidelines of #AAIC: Pathways to Adoption: Translating Insights into Action for Diagnostic Innovations.  Register here: https://lnkd.in/eHZ63RhC   Together, we are revolutionizing Alzheimer's diagnostics and promoting the widespread adoption of BBM tests! 

Conventional Alzheimer’s diagnostic processes have long been costly, time-consuming, and challenging to access. Now, Alzheimer's blood tests, conducted by primary care physicians, are changing the landscape. These tests offer a more affordable, efficient, and accessible option, significantly reducing diagnosis wait times and making critical healthcare more reachable for patients everywhere. Learn more about the future of Alzheimer's blood tests and how CEOi's Blood-based Biomarker Workgroup is working to educate the primary care field on implementing these tests into their own practices. https://lnkd.in/eKjVepki

Breaking News: The FDA approved a new amyloid-targeting therapy to treat adults with early symptomatic #AlzheimersDisease. Learn more: https://e.lilly/4bsaOPk

More exciting progress in the blood-based biomarker space! We're proud to promote the amazing work by CEOi's BBM Workgroup Leader Suzanne Schindler on impactful research comparing Alzheimer's disease blood tests. Check out her post and click here to read the pre-print: https://lnkd.in/gMP_vm67

Join us for a lunch and panel discussion on the sidelines of #AAIC: Pathways to Adoption: Translating Insights into Action for Diagnostic Innovations. Hear from leading Alzheimer's experts as they share their insights on on the state of Alzheimer's diagnostics, the latest breakthroughs and actionable strategies to accelerate the adoption of cutting-edge diagnostic technologies. Barak Gaster- University of Washington - School of Medicine Suzanne Schindler - Washington University in St. Louis Karen K. Tracy - Gerontological Society of America (GSA) Julie Wood - American Academy of Family Physicians Date: July 30th 2024 Time: 12:30-1:45pm ET Location: The Notary Hotel, Autograph Collection 21 North Juniper Street, Philadelphia, PADon't miss this unique opportunity to be at the forefront of diagnostic advancements in Alzheimer’s! Register Here: https://lnkd.in/eT9apHTS

Check out this article in Health Policy Watch that highlights CEOi's publication in Nature Reviews Neurology, "Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease" and our partners at Davos Alzheimer's Collaborative's #AccurateDiagnosis project, which is the first ever global implementation research program to study the use of #bloodbasedbiomarkers. Read the article here to learn more about these transformative initiatives: https://lnkd.in/eNpMF-rJ And don't forget to check CEOi's website: www.alzbiomarkerhub.org

“What prompted this effort was trying to define how good these blood tests need to be to be appropriate for clinical use,” said Suzanne Schindler, Neurologist at Washington University School of Medicine and Blood-Based Biomarker (BBM) Workgroup Co-Lead. So, what does a good blood test look like? With leadership from @ Suzanne and @ Oskar and 90+ expert members, the BBM Workgroup set a high bar for performance standards for #Alzheimers #bloodtests. Read the full recommendations in our recent publication in @ Nature Reviews Neurology here: https://lnkd.in/eaReXM3Q And check out Suzanne’s video here:  https://lnkd.in/eppNj5WF Together, we are transforming the future of Alzheimer’s diagnostics and paving the way for the widespread adoption of BBM tests! To stay up to date on the BBM Workgroup and discover educational resources and the latest news in the BBM space, visit www.alzbiomarkerhub.org.

Blood-based biomarker (BBM) tests for Alzheimer’s disease (AD) have the potential to bring earlier and more accurate diagnoses to patients. That’s why we’re proud to be part of the CEOi - Global CEO Initiative on Alzheimer's Disease BBM Workgroup and announce the publication of “The Global CEO Initiative on Alzheimer’s Disease performance recommendations for blood-based biomarker tests” in Nature Reviews Neurology. Read more here: https://ow.ly/LrxM50Shgzo

We are thrilled to announce a major milestone in the diagnosis of Alzheimer's disease with the publication of the first performance recommendations for blood-based biomarker (BBM) tests for Alzheimer’s disease. Crafted by more than 90 leading experts in the field, the CEOi BBM Workgroup standards are now available in Nature Reviews Neurology. Continued advancements related to Alzheimer’s disease-modifying treatments are providing new hope to patients. However, for these tools to reach patients, accurate and timely diagnosis is critical. Blood tests for Alzheimer's could revolutionize Alzheimer's diagnosis since they are more affordable and accessible compared to existing tools. However, without clear standards, understanding how and where to use BBMs was a major barrier. To address this challenge, CEOi convened stakeholders from healthcare, academia, non-profit, government, industry, and patient advocacy. Key recommendations include: - Use of BBM tests to confirm disease pathology without further PET or CSF testing, or use as a triaging tool with subsequent confirmatory testing. - When used in triaging, tests should demonstrate at least 90% sensitivity, and at least 85% specificity in primary care or 75% in secondary care settings. - When used as a confirmatory tool, performance standards should be equivalent to cerebrospinal fluid (CSF) tests, which is 90% sensitivity and specificity. To learn more about the BBM Workgroup visit our website here: www.alzbiomarkerhub.org and read the publication here: https://lnkd.in/eaReXM3Q Thank you to all the authors who made this achievement possible! Suzanne Schindler Oskar Hansson Douglas Galasko Ana Pereira, M.D. Gil Rabinocivi Stephen Salloway Marc Suárez-Calvet Ara Khachaturian Michelle Mielke Dr Chi Udeh-Momoh Joan Weiss Richard Batrla, MD, PhD, MBA Sasha Bozeat John Dwyer Drew Holzapfel Daryl Rhys Jones, PhD Jim Murray Katie Partrick, Ph.D. Emily Scholler, MPH Ben Tiede George Vradenburg Dylan Young Alicia Algeciras-Schimnich Jiri Aubrecht Joel Braunstein, MD James Hendrix Yan (Helen) Hu, PhD Soeren Mattke Mark Monane, MD, MBA David Reilly Elizabeth Somers Charlotte Teunissen Eli Shobin Hugo Vanderstichele Michael Weiner David Wilson

We are thrilled to announce a major milestone in the diagnosis of Alzheimer's disease with the publication of the first performance recommendations for blood-based biomarker (BBM) tests for Alzheimer’s disease. Crafted by more than 90 leading experts in the field, the CEOi BBM Workgroup standards are now available in Nature Reviews Neurology. Continued advancements related to Alzheimer’s disease-modifying treatments are providing new hope to patients. However, for these tools to reach patients, accurate and timely diagnosis is critical. Blood tests for Alzheimer's could revolutionize Alzheimer's diagnosis since they are more affordable and accessible compared to existing tools. However, without clear standards, understanding how and where to use BBMs was a major barrier. To address this challenge, CEOi convened stakeholders from healthcare, academia, non-profit, government, industry, and patient advocacy. Key recommendations include: - Use of BBM tests to confirm disease pathology without further PET or CSF testing, or use as a triaging tool with subsequent confirmatory testing. - When used in triaging, tests should demonstrate at least 90% sensitivity, and at least 85% specificity in primary care or 75% in secondary care settings. - When used as a confirmatory tool, performance standards should be equivalent to cerebrospinal fluid (CSF) tests, which is 90% sensitivity and specificity. To learn more about the BBM Workgroup visit our website here: www.alzbiomarkerhub.org and read the publication here: https://lnkd.in/eaReXM3Q Thank you to all the authors who made this achievement possible! Suzanne Schindler Oskar Hansson Douglas Galasko Ana Pereira, M.D. Gil Rabinocivi Stephen Salloway Marc Suárez-Calvet Ara Khachaturian Michelle Mielke Dr Chi Udeh-Momoh Joan Weiss Richard Batrla, MD, PhD, MBA Sasha Bozeat John Dwyer Drew Holzapfel Daryl Rhys Jones, PhD Jim Murray Katie Partrick, Ph.D. Emily Scholler, MPH Ben Tiede George Vradenburg Dylan Young Alicia Algeciras-Schimnich Jiri Aubrecht Joel Braunstein, MD James Hendrix Yan (Helen) Hu, PhD Soeren Mattke Mark Monane, MD, MBA David Reilly Elizabeth Somers Charlotte Teunissen Eli Shobin Hugo Vanderstichele Michael Weiner David Wilson